Tagged with IoT

Switzerland Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and Gilead. In an exclusive interview, Riva outlines his motivations behind taking on this new challenge, how the company’s approach to oncology treatment differs from  – and…

China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.   AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…

Singapore ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead asset has the potential to compete with Sanofi’s blockbuster Dupixent and why ASLAN decided to delist from the Taiwan Stock…

China One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province, part of the Yangtze River Delta, where the Yangtze River feeds into the East China Sea. Founded initially in 1971,…

USA Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan therapies in Europe, here we move to the world’s biggest biopharmaceutical market and R&D hub, shining the spotlight on five of the most important and innovative rare-disease start-ups in the USA.   The US…

China HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in microbial engineering and chemical engineering and a PhD in molecular biology and genetics, an academic career at top US institutions…

China Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other biotech leaders.   The traditional bulk analysis method is well-established and suited for diseases that are more homogenous, but cancer…

Europe With Rare Disease Day falling on 28 February, PharmaBoardroom dedicates this month to exploring the global rare disease landscape, highlighting key trends and developments as well as profiling the most innovative global players in this space. We start the party off with five of the most promising clinical-stage biotech companies…

Switzerland Dr Chris Martin, CEO and co-founder of Swiss-headquartered antibody-drug conjugate cancer company, ADC Therapeutics, shares the company’s journey over the past decade, the exciting progress of their two lead candidates, the process of building their commercial organization in the US, and his perspectives on Big Pharma partnerships.   We have…

Switzerland In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical breakthroughs, and why scientific innovation continues to motivate him.   When you have started two companies, people think that you…

China While many parts of the world ground to a halt as they tried to deal with the global pandemic, China had more or less brought the situation under control by June, and the healthcare deals engine just kept on churning. MSQ Ventures recently published its 2020 China Biopharma Global Transactions…

Global Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six of the seven companies are from China, pointing to the massive growth of the Chinese biotech market.   Remegen RemeGen,…